Feng JH - Search Results

1

Preparation and antitumor activity of a tamibarotene-furoxan derivative.

Wang XJ, Duan Y, Li ZT, Feng JH, Pan XP, Zhang XR, Shi LH, Zhang T. Wang XJ, et al. Among authors: feng jh. Asian Pac J Cancer Prev. 2014;15(15):6343-7. doi: 10.7314/apjcp.2014.15.15.6343. Asian Pac J Cancer Prev. 2014. PMID: 25124622 Free article.

2

LYP3, a new bestatin derivative for aminopeptidase N inhibition.

Luan Y, Ma C, Sui Z, Wang X, Feng J, Liu N, Jing F, Wang Y, Li M, Fang H, Xu W. Luan Y, et al. Med Chem. 2011 Jan;7(1):32-6. doi: 10.2174/157340611794072706. Med Chem. 2011. PMID: 21235517

3

Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.

Feng J, Fang H, Wang X, Jia Y, Zhang L, Jiao J, Zhang J, Gu L, Xu W. Feng J, et al. Cancer Biol Ther. 2011 Mar 1;11(5):477-89. doi: 10.4161/cbt.11.5.14529. Epub 2011 Mar 1. Cancer Biol Ther. 2011. PMID: 21263218 Free article.

4

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

Zhang Y, Feng J, Jia Y, Wang X, Zhang L, Liu C, Fang H, Xu W. Zhang Y, et al. J Med Chem. 2011 Apr 28;54(8):2823-38. doi: 10.1021/jm101605z. Epub 2011 Apr 5. J Med Chem. 2011. PMID: 21476600

5

Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.

Zhang Y, Fang H, Feng J, Jia Y, Wang X, Xu W. Zhang Y, et al. J Med Chem. 2011 Aug 11;54(15):5532-9. doi: 10.1021/jm200577a. Epub 2011 Jul 11. J Med Chem. 2011. PMID: 21714538

6

Discovery of novel vascular endothelial growth factor receptor 2 inhibitors: a virtual screening approach.

Zhang L, Wang X, Feng J, Jia Y, Xu F, Xu W. Zhang L, et al. Chem Biol Drug Des. 2012 Dec;80(6):893-901. doi: 10.1111/cbdd.12036. Chem Biol Drug Des. 2012. PMID: 22913881

7

Discovery of N-(2-Amino-4-Fluorophenyl)-4-[bis-(2-Chloroethyl)-Amino]-Benzamide as a Potent HDAC3 Inhibitor.

Chen Y, Feng J, Hu Y, Wang X, Song W, Zhang L. Chen Y, et al. Front Oncol. 2020 Oct 15;10:592385. doi: 10.3389/fonc.2020.592385. eCollection 2020. Front Oncol. 2020. PMID: 33178617 Free PMC article.

8

Novel antileukemic agents derived from tamibarotene and nitric oxide donors.

Bian H, Feng J, Li M, Xu W. Bian H, et al. Bioorg Med Chem Lett. 2011 Dec 1;21(23):7025-9. doi: 10.1016/j.bmcl.2011.09.103. Epub 2011 Oct 1. Bioorg Med Chem Lett. 2011. PMID: 22014829

9

Discovery and SAR analysis of 5-chloro-4-((substituted phenyl)amino)pyrimidine bearing histone deacetylase inhibitors.

Zhang L, Chen Y, Li F, Zhang L, Feng J, Zhang L. Zhang L, et al. J Enzyme Inhib Med Chem. 2022 Dec;37(1):1918-1927. doi: 10.1080/14756366.2022.2097446. J Enzyme Inhib Med Chem. 2022. PMID: 35833370 Free PMC article.

10

Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.

Zhang Y, Feng J, Liu C, Fang H, Xu W. Zhang Y, et al. Bioorg Med Chem. 2011 Aug 1;19(15):4437-44. doi: 10.1016/j.bmc.2011.06.046. Epub 2011 Jun 21. Bioorg Med Chem. 2011. PMID: 21733698

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

270 results

Search Page

Filters